High Incidence of Herpes Zoster After Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis | Zendy

Elisabetta Xue | Zendy; Hu Xie | Zendy; Wendy M. Leisenring | Zendy; Louise E. Kimball | Zendy; Sonia Goyal | Zendy; E Chung | Zendy; Rachel Blazevic | Zendy; Byron Maltez | Zendy; A. S. Edwards | Zendy; Ann Dahlberg | Zendy; Rachel B. Salit | Zendy; Colleen Delaney | Zendy; Steven A. Pergam | Zendy; Michael Boeckh | Zendy; Filippo Milano | Zendy; Joshua A. Hill | Zendy

Open Access

High Incidence of Herpes Zoster After Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis

Author(s) -

Elisabetta Xue,

Hu Xie,

Wendy M. Leisenring,

Louise E. Kimball,

Sonia Goyal,

E Chung,

Rachel Blazevic,

Byron Maltez,

A. S. Edwards,

Ann Dahlberg,

Rachel B. Salit,

Colleen Delaney,

Steven A. Pergam,

Michael Boeckh,

Filippo Milano,

Joshua A. Hill

Publication year - 2020

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciaa222

Subject(s) - medicine , cumulative incidence , hazard ratio , incidence (geometry) , confidence interval , proportional hazards model , context (archaeology) , cohort , hematopoietic cell , surgery , haematopoiesis , paleontology , physics , genetics , stem cell , optics , biology

Cord blood transplant (CBT) recipients have a high incidence of herpes zoster (HZ) in the context of short-term peritransplant antiviral prophylaxis. In 2009, international guidelines recommended HZ prophylaxis for at least 1 year after hematopoietic cell transplant. The impact of longer-term antiviral prophylaxis on HZ incidence after CBT is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research